Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
about
Gene therapy in Parkinson's disease: rationale and current statusOligonucleotide therapeutic approaches for Huntington diseaseAn optogenetic toolbox designed for primatesTheoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's DiseaseNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesLipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's DiseaseMerging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's diseaseParkinson's disease: gene therapiesParkinson's disease gene therapy: success by design meets failure by efficacyGlial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brainTreating Parkinson's disease in the 21st century: can stem cell transplantation compete?Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned ratsNoninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound.Therapeutic potential of optogenetic neuromodulationNoninvasive, neuron-specific gene therapy can be facilitated by focused ultrasound and recombinant adeno-associated virusEnhancement of Blood-Brain Barrier Permeability and Delivery of Antisense Oligonucleotides or Plasmid DNA to the Brain by the Combination of Bubble Liposomes and High-Intensity Focused Ultrasound.Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy.A diagnostic approach for cerebral palsy in the genomic era.Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects.Current Experimental Studies of Gene Therapy in Parkinson's DiseaseTransduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapyHuman/nonhuman primate AC-PC ratio--considerations for translational brain measurementsTherapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy.The current status of gene therapy for Parkinson's diseaseRegeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.Guided delivery of adeno-associated viral vectors into the primate brainA phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's diseaseSAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer.Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's diseaseGene therapy in mouse models of huntington disease.Gene therapy for the nervous system: challenges and new strategies.Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.
P2860
Q22241423-E2B77D06-A32D-42AD-BA48-25C5794EAA74Q22306293-49D0EC95-BF59-4F3F-B942-24FC2CC90018Q24623252-3C07CB34-7B9B-447A-BBDA-48F53EA55427Q26746174-A6A717FB-2AE3-49EA-A2DC-C0B775EC29BEQ26747508-9347E622-F9E6-4C5A-AC10-177D189BF1DEQ26752578-0BBE8D78-4DDA-422A-B0D4-B746FDBE1133Q26773485-D088E784-DE79-48CF-9DEF-96CE57228A20Q26824184-6A8DA629-F673-4CBD-A49A-905F8CCF85E7Q26851325-DDC6A109-2AAC-4A83-8A81-E3F5C401A348Q27002651-4D62DF9D-1CEF-4A5C-8D6B-82265C10A2F0Q27024152-A537C6E6-AC7B-4E7E-8F44-0E676DDECE06Q27310170-E77B1CDA-B4D3-47FA-815B-A8E5BF7B11B2Q27312535-81D67651-3368-4061-8438-65527E15F9EAQ28084334-05E3D73B-16B0-487B-A100-51569E67652AQ30394725-D6AA5D40-3771-4530-8F69-F9EEA7E7D831Q30401360-FB31EA76-486C-4F37-ADEC-2E790BB974FBQ30531601-8BF40AF3-4591-46C8-B858-2B92FDE303E5Q30605561-B0FDA102-C4F5-4486-8991-2A0A89EE38F3Q30857266-C0CDE671-C128-4DE3-8CD5-70DED3DCBBEFQ33600773-8DC38F47-3692-48E8-B6F4-6B075F54F6B4Q33627771-06724A9B-E3ED-418D-973F-6EFDC6C13326Q33700352-B7BC82F1-2A61-4AB4-8CDF-88DB8D048A37Q33780449-975A6BF7-485C-4867-9B9D-49D81BE6D842Q33807060-6B22EA04-0086-455B-AC7F-1869700BBED3Q33853332-BF16DC48-F478-4015-8240-ED27B3599328Q33938435-4D8D6ECE-68D1-494C-B81C-F14B45C645C2Q33973505-1DCEDB69-AF70-4692-B6EB-0DDC606BD0F0Q33979379-E6F64D0E-ECAB-446B-A88D-FD799A6A460AQ34039452-4DAB21ED-FEFA-4F2F-B69C-7DB091A34820Q34061373-E444B27F-3F77-4C1C-A706-3AE32B1877BFQ34209755-E30B4FFD-A8AF-4707-B48F-4BE1B7F1BEF8Q34762396-F1CC120E-D077-4CF0-BF66-3D02AB5B60F2Q34795088-7BCA6D59-A935-4FC8-AE60-A945F4DDCC50Q34892014-3B23C118-AA30-4DA9-9CAD-97D86232D219Q34954951-F594DFDC-0CCE-4F3F-92C6-82E05E009ADDQ35086686-2D1C0262-EBDC-4C60-B18B-7BE52F7C7402Q35090208-E10C5742-3ADC-4E79-9C91-0048788B4969Q35340196-3145BB53-082D-4877-B1F8-39CFCD17E92CQ35582092-B47CCB0A-829A-4E82-B92C-116FFD0D5F6BQ35614156-1874403C-FC0A-46C7-AA87-398F79101FF1
P2860
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
@ast
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
@en
type
label
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
@ast
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
@en
prefLabel
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
@ast
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
@en
P2093
P2860
P1433
P1476
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
@en
P2093
C W Christine
H F VanBrocklin
J F Wright
J L Eberling
K S Bankiewicz
M J Aminoff
P S Larson
R A Hawkins
W J Jagust
P2860
P304
P356
10.1212/WNL.0B013E3181C29356
P407
P577
2009-10-14T00:00:00Z